BioLife Solutions, Inc. (BLFS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

33.95+0.36 (+1.07%)

As of 11:25AM EDT. Market open.

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Commodity Channel Index

View all chart patterns

Performance Outlook

Previous Close	33.59
Open	33.80
Bid	33.65 x 900
Ask	33.70 x 800
Day's Range	33.30 - 33.84
52 Week Range	9.93 - 47.97
Volume	81,984
Avg. Volume	309,262

Market Cap	1.134B
Beta (5Y Monthly)	1.49
PE Ratio (TTM)	N/A
EPS (TTM)	-0.04
Earnings Date	May 12, 2021 - May 17, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	56.25

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-64% Est. Return

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

PR Newswire
BioLife Solutions Launches New High Capacity Controlled Rate Freezer Line with First Shipment to a Leading Cell Therapy Developer
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that it has launched a new line of high capacity controlled rate freezers (HCRF), with an initial shipment to a leading cell therapy company. The freezer will be a critical component in this customer's cold chain management of several allogeneic cell therapies in development.
- NKGen Biotech Announces Appointment of Steven Cha, MD as Chief Medical Officer
  GlobeNewswire
- ImCheck Therapeutics Appoints Dr. Loui Madakamutil as CSO
  GlobeNewswire
Zacks
HRC or BLFS: Which Is the Better Value Stock Right Now?
HRC vs. BLFS: Which Stock Is the Better Value Option?
PR Newswire
BioLife Solutions Appoints Two New Independent Board Directors
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that it has appointed Amy DuRoss, chief executive officer of Vineti, and Rachel Ellingson, senior vice president and chief strategy officer at Zimmer Biomet to its board of directors effective immediately.